Literature DB >> 17509395

Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma with a complex karyotype and cryptic 3' ALK gene insertion to chromosome 4 q22-24.

Dariusz Stachurski1, Patricia Minehart Miron, Samer Al-Homsi, Lloyd Hutchinson, Nancy Lee Harris, Bruce Woda, Sa A Wang.   

Abstract

Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare tumor that is frequently associated with t(2;17)(p23;q23), a translocation fusing the ALK gene at 2p23 to the clathrin heavy chain gene (CLTC) at 17q23. Here, we report a unique case of ALK-positive DLBCL with plasmablastic morphology and focal cytoplasmic granular ALK stain in an HIV-negative 33-year-old man. By conventional karyotyping, the lymphoma cells were near-tetraploid and included 4 structurally normal copies each of chromosomes 2 and 17. Fluorescence in situ hybridization revealed an apparently normal, intact ALK gene on each of the 4 chromosome 2 homologs plus a cytogenetically cryptic ALK gene insertion into 2 of the 4 chromosome 4 homologs at band 4q22-24. The lymphoma cells expressed CD138, lambda light chain, focal and weak CD30, and exhibited aberrant T-cell antigens, including perforin. This case indicates that ALK-positive DLBCL is more heterogeneous at the cytogenetic/molecular level than previously recognized.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17509395     DOI: 10.1016/j.humpath.2006.12.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  An unusual case of anaplastic lymphoma kinase-positive large B-cell lymphoma in an elderly patient: A case report and discussion.

Authors:  Hanzhen Xiong; Shao-Yan Liu; Yue-Xin Yang; Xue-Xian Tan; Qiu-Ping Luo; Juan Peng; Zhong-Tang Xiong; Hui Chen; Juan Chen; Zhi Li; Qing-Ping Jiang
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

2.  ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.

Authors:  Katrien Van Roosbroeck; Jan Cools; Daan Dierickx; José Thomas; Peter Vandenberghe; Michel Stul; Jan Delabie; Chris De Wolf-Peeters; Peter Marynen; Iwona Wlodarska
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

Review 3.  ALK-immunoreactive neoplasms.

Authors:  Parham Minoo; Huan-You Wang
Journal:  Int J Clin Exp Pathol       Date:  2012-05-23

4.  Promising response of anaplastic lymphoma kinase-positive large B-cell lymphoma to crizotinib salvage treatment: case report and review of literature.

Authors:  Jian Li; Jian Ouyang; Rongfu Zhou; Bing Chen; Yong Xu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

5.  Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity.

Authors:  Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2009-03-13

Review 6.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

7.  Pathobiology of anaplastic large cell lymphoma.

Authors:  Pier Paolo Piccaluga; Anna Gazzola; Claudia Mannu; Claudio Agostinelli; Francesco Bacci; Elena Sabattini; Carlo Sagramoso; Roberto Piva; Fernando Roncolato; Giorgio Inghirami; Stefano A Pileri
Journal:  Adv Hematol       Date:  2011-02-06

8.  Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma.

Authors:  Elizabeth A Morgan; Alessandra F Nascimento
Journal:  Adv Hematol       Date:  2012-02-26

9.  Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies.

Authors:  N K El-Mallawany; J K Frazer; P Van Vlierberghe; A A Ferrando; S Perkins; M Lim; Y Chu; M S Cairo
Journal:  Blood Cancer J       Date:  2012-04-13       Impact factor: 11.037

Review 10.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.